GlassScriptPhysician profile
Ray S Corbin-Simon
NPI 1871652081
$15,923.15
in general payments reported to CMS, 2019-2025
29 companies · $2,902 in 2025
The $2,902 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,262 · 2020: $587 · 2021: $535 · 2022: $274 · 2023: $2,923 · 2024: $7,440 · 2025: $2,902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $2,660 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,504.47 |
| Travel and Lodging | $2,660.38 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $7,319.01 | 2023-2024 | M22, Optilight |
| Coopervision INC. | $2,249.83 | 2019-2025 | Myday Contact Lens, Paragon Crt, Clariti Contact Lens |
| Johnson & Johnson Vision Care, INC. | $1,863.21 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $688.28 | 2019-2025 | Rocklatan, Precision 1, Rhopressa |
| Synergeyes, INC. | $520.76 | 2019 | |
| Bausch & Lomb Americas INC. | $488.76 | 2023-2025 | Miebo, Vyzulta, Infuse |
| Tarsus Pharmaceuticals, INC. | $331.25 | 2024-2025 | Xdemvy |
| Allergan, INC. | $273.29 | 2019-2021 | |
| Oyster Point Pharma, INC. | $220.26 | 2022-2024 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $219.42 | 2019-2025 | Cequa |
| Eyevance Pharmaceuticals LLC | $195.93 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $188.05 | 2024-2025 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $187.98 | 2020-2021 | |
| Abb Con-Cise Optical Group LLC | $187.34 | 2024 | Spectacle Lenses, Contact Lens |
| Novartis Pharmaceuticals Corporation | $148.63 | 2019-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $121.75 | 2021 | |
| Visioneering Technologies, INC. | $114.21 | 2019 | |
| Aerie Pharmaceuticals, INC. | $104.81 | 2019 | |
| Abbvie INC. | $101.30 | 2023 | Vuity |
| Kala Pharmaceuticals, INC. | $92.29 | 2021-2022 | |
| Genzyme Corporation | $87.47 | 2022 | |
| Shire North American Group INC | $58.21 | 2019 | |
| Glaukos Corporation | $37.24 | 2021 | |
| Lkc Technologies, INC. | $29.41 | 2024 | |
| Optos, INC. | $22.07 | 2020 | |
| Biotissue Holdings INC. | $20.69 | 2023 | |
| Harrow Eye, LLC | $18.00 | 2025 | Vevye |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Thea Pharma INC. | $16.46 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ray Corbin-Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.